196 related articles for article (PubMed ID: 35770395)
1. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.
Lu X
Curr Med Chem; 2022; 29(41):6228-6246. PubMed ID: 35770395
[TBL] [Abstract][Full Text] [Related]
2. CX3CL1 Signaling in the Tumor Microenvironment.
Conroy MJ; Lysaght J
Adv Exp Med Biol; 2020; 1231():1-12. PubMed ID: 32060841
[TBL] [Abstract][Full Text] [Related]
3. The miR-561-5p/CX
Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
[TBL] [Abstract][Full Text] [Related]
4. The CX3CL1/CX3CR1 axis is upregulated in chronic kidney disease and contributes to angiotensin II-induced migration of vascular smooth muscle cells.
Li C; Zhong X; Xia W; He J; Gan H; Zhao H; Xia Y
Microvasc Res; 2020 Nov; 132():104037. PubMed ID: 32615135
[TBL] [Abstract][Full Text] [Related]
5. Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
Cormican S; Griffin MD
Front Immunol; 2021; 12():664202. PubMed ID: 34163473
[TBL] [Abstract][Full Text] [Related]
6. Role of the CX
Hamdan D; Robinson LA
Am J Physiol Renal Physiol; 2021 Aug; 321(2):F121-F134. PubMed ID: 34121453
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model.
Seo Y; Kim HS; Kang I; Choi SW; Shin TH; Shin JH; Lee BC; Lee JY; Kim JJ; Kook MG; Kang KS
Glia; 2016 Dec; 64(12):2291-2305. PubMed ID: 27687148
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.
Poniatowski ŁA; Wojdasiewicz P; Krawczyk M; Szukiewicz D; Gasik R; Kubaszewski Ł; Kurkowska-Jastrzębska I
Mol Neurobiol; 2017 Apr; 54(3):2167-2188. PubMed ID: 26927660
[TBL] [Abstract][Full Text] [Related]
9. Fractalkine/CX3CL1 in Neoplastic Processes.
Korbecki J; Simińska D; Kojder K; Grochans S; Gutowska I; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466280
[TBL] [Abstract][Full Text] [Related]
10. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
[TBL] [Abstract][Full Text] [Related]
11. Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies.
Ferretti E; Pistoia V; Corcione A
Mediators Inflamm; 2014; 2014():480941. PubMed ID: 24799766
[TBL] [Abstract][Full Text] [Related]
12. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
Zhuang Q; Cheng K; Ming Y
Curr Gene Ther; 2017; 17(6):442-452. PubMed ID: 29446734
[TBL] [Abstract][Full Text] [Related]
13. CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status.
Ni Y; Zhuge F; Ni L; Nagata N; Yamashita T; Mukaida N; Kaneko S; Ota T; Nagashimada M
Metabolism; 2022 Nov; 136():155272. PubMed ID: 35914622
[TBL] [Abstract][Full Text] [Related]
14. Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction.
Roy-Chowdhury E; Brauns N; Helmke A; Nordlohne J; Bräsen JH; Schmitz J; Volkmann J; Fleig SV; Kusche-Vihrog K; Haller H; von Vietinghoff S
Cardiovasc Res; 2021 May; 117(6):1510-1522. PubMed ID: 32717023
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine induces angiogenic potential in CX3CR1-expressing monocytes.
Park Y; Lee J; Kwak JY; Noh K; Yim E; Kim HK; Kim YJ; Broxmeyer HE; Kim JA
J Leukoc Biol; 2018 Jan; 103(1):53-66. PubMed ID: 28978662
[TBL] [Abstract][Full Text] [Related]
16. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling.
Frias-Anaya E; Gallego-Gutierrez H; Gongol B; Weinsheimer S; Lai CC; Orecchioni M; Sriram A; Bui CM; Nelsen B; Hale P; Pham A; Shenkar R; DeBiasse D; Lightle R; Girard R; Li Y; Srinath A; Daneman R; Nudleman E; Sun H; Guma M; Dubrac A; Mesarwi OA; Ley K; Kim H; Awad IA; Ginsberg MH; Lopez-Ramirez MA
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1246-1264. PubMed ID: 38660801
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between the CX3CL1/CX3CR1 Axis and Inflammatory Signaling Pathways in Tissue Injury.
Zhuang Q; Ou J; Zhang S; Ming Y
Curr Protein Pept Sci; 2019; 20(8):844-854. PubMed ID: 30843484
[TBL] [Abstract][Full Text] [Related]
18. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.
Wojdasiewicz P; Poniatowski LA; Kotela A; Deszczyński J; Kotela I; Szukiewicz D
Arch Immunol Ther Exp (Warsz); 2014 Oct; 62(5):395-403. PubMed ID: 24556958
[TBL] [Abstract][Full Text] [Related]
19. Expression changes of CX3CL1 and CX3CR1 proteins in the hippocampal CA1 field of the gerbil following transient global cerebral ischemia.
Ahn JH; Kim DW; Park JH; Lee TK; Lee HA; Won MH; Lee CH
Int J Mol Med; 2019 Sep; 44(3):939-948. PubMed ID: 31524247
[TBL] [Abstract][Full Text] [Related]
20. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
